Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 25 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

On 6ix: 6ix.com/news/press-release-apr-25-2026-6

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases